Abobotulinumtoxina
Products billed under this code include Dysport.
Payment limit per 5 Unit, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Dysport.
Payment limit per 5 Unit, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Dysport | Galderma Laboratories, L.P. | 00299-5962-30 | 60 | $536.22 |
| Dysport | Ipsen Biopharmaceuticals, Inc. | 15054-0500-01 | 100 | $893.70 |
| Dysport | Ipsen Biopharmaceuticals, Inc. | 15054-0530-06 | 60 | $536.22 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $8.937 | −$0.009 | 5 Unit | Abobotulinumtoxina | v1, posted September 17, 2026 |
| 3Q26 | $8.946 | +$0.043 | 5 Unit | Abobotulinumtoxina | v1, posted September 15, 2026 |
| 2Q26 | $8.903 | +$0.104 | 5 Unit | Abobotulinumtoxina | v1, posted September 15, 2026 |
| 1Q26 | $8.799 | +$0.047 | 5 Unit | Abobotulinumtoxina | v1, posted September 15, 2026 |
| 4Q25 | $8.752 | −$0.418 | 5 Unit | Abobotulinumtoxina | v1, posted September 8, 2026 |
| 3Q25 | $9.17 | +$0.126 | 5 Unit | Abobotulinumtoxina | v1, posted March 10, 2026 |
| 2Q25 | $9.044 | +$0.518 | 5 Unit | Abobotulinumtoxina | v1, posted March 10, 2026 |
| 1Q25 | $8.526 | −$0.104 | 5 Unit | Abobotulinumtoxina | v1, posted December 19, 2025 |
| 4Q24 | $8.63 | −$0.082 | 5 Unit | Abobotulinumtoxina | v1, posted June 11, 2025 |
| 3Q24 | $8.712 | +$0.03 | 5 Unit | Abobotulinumtoxina | v1, posted June 11, 2025 |
| 2Q24 | $8.682 | −$0.123 | 5 Unit | Abobotulinumtoxina | v1, posted March 11, 2025 |
| 1Q24 | $8.805 | +$0.008 | 5 Unit | Abobotulinumtoxina | v1, posted December 19, 2024 |
| 4Q23 | $8.797 | +$0.196 | 5 Unit | Abobotulinumtoxina | v1, posted October 10, 2024 |
| 3Q23 | $8.601 | −$0.101 | 5 Unit | Abobotulinumtoxina | v1, posted June 5, 2024 |
| 2Q23 | $8.702 | −$0.029 | 5 Unit | Abobotulinumtoxina | v1, posted February 23, 2024 |
| 1Q23 | $8.731 | +$0.104 | 5 Unit | Abobotulinumtoxina | v1, posted December 6, 2023 |
| 4Q22 | $8.627 | +$0.107 | 5 Unit | Abobotulinumtoxina | v1, posted June 22, 2023 |
| 3Q22 | $8.52 | +$0.118 | 5 Unit | Abobotulinumtoxina | v1, posted June 9, 2023 |
| 2Q22 | $8.402 | +$0.093 | 5 Unit | Abobotulinumtoxina | v1, posted December 14, 2022 |
| 1Q22 | $8.309 | −$0.099 | 5 Unit | Abobotulinumtoxina | v1, posted June 8, 2022 |
| 4Q21 | $8.408 | +$0.212 | 5 Unit | Abobotulinumtoxina | v1, posted June 2, 2022 |
| 3Q21 | $8.196 | −$0.053 | 5 Unit | Abobotulinumtoxina | v1, posted June 2, 2022 |
| 2Q21 | $8.249 | −$0.021 | 5 Unit | Abobotulinumtoxina | v1, posted March 1, 2022 |
| 1Q21 | $8.27 | – | 5 Unit | Abobotulinumtoxina | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.